secwatch.observer — SEC 8-K summary
======================================

Issuer:     Frazier Lifesciences Acquisition Corp (—)
CIK:        0001828326
Form:       8-K
Filed at:   2022-11-23T23:59:59+00:00
Accession:  0001193125-22-292061
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam Pharma begins trading as NAMS after $328M SPAC merger with FLAC
----------------------------------------------------------------------------

- Gross proceeds of ~$328M from trust ($93M) and upsized PIPE ($235M) extend cash runway into 2026.
- FLAC shareholders redeemed ~32% of shares (4.57M shares, ~$46.1M) prior to merger close.
- Lead asset obicetrapib in Phase 3; BROADWAY and BROOKLYN data expected in 2024, PREVAIL CVOT in 2026.
- Michael Davidson remains CEO; former FLAC directors resigned; new board appointed post-merger.
- FLAC securities delisted; combined company's shares and warrants begin trading on Nasdaq as NAMS and NAMSW.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828326/000119312522292061/0001193125-22-292061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828326/000119312522292061/d426932d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-292061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer